ARK bought 200,303 RKLB shares through its flagship ARK Innovation ETF, a $12.8 million transaction.

Morgan Stanley expects investor focus to shift to readouts from the next part of the same trial in patients with severe hypertriglyceridemia due in the back half of the year and other second-half readouts.

ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.

Cathie Wood’s ARK Investment Management bought a total of 57,705 AVGO shares across three of its funds.

Total purchases of Cerebras stock by Wood’s ARK Invest in August are over $60 billion, according to disclosures.

CoreWeave expanded its partnership with Rescale to support AI and simulation workloads.

In an interview with CNBC, Brian Armstrong said he is “pretty optimistic” that the CLARITY Act will receive more than 60 votes in the Senate in September.

Wood said soaring memory prices will encourage engineers to develop cheaper alternatives and attract additional supply.

Cathie Wood’s Ark Invest bought 160,890 Rocket Lab shares for its flagship ARK Innovation ETF worth about $12.7 million at current levels.